Semaglutide vs Tirzepatide: Which Works Better?

If you are choosing between semaglutide and tirzepatide — or wondering whether the one you are on is the "best" option — you are asking the most useful question in this whole drug class. These two medicines dominate GLP-1 weight management, and for the first time there is a direct, head-to-head randomized trial that pits them against each other. The short version: tirzepatide produced more weight loss in that trial. The honest version, which is what this guide is about, is that the gap is real but not enormous, the side-effect profiles differ in ways that matter to real people, and "better on average" is not the same as "better for you."

A grounding fact first. Semaglutide is a single-receptor drug — it activates the GLP-1 receptor. It is sold as Wegovy (for chronic weight management), Ozempic (for type 2 diabetes), and Rybelsus/oral Wegovy (the pill form). Tirzepatide is a dual agonist — it activates both the GLP-1 receptor and the GIP receptor — and is sold as Zepbound (weight management) and Mounjaro (diabetes). That one mechanistic difference is the headline of the whole comparison: one hormone pathway versus two. (Because semaglutide wears several brand names, it helps to first sort out Ozempic vs Wegovy — same drug, different label.)

The head-to-head trial: tirzepatide came out ahead

For years, comparisons between these two drugs were indirect — you lined up the semaglutide trials next to the tirzepatide trials and squinted. That is unreliable, because the trial populations and designs differ. In 2025 that changed: SURMOUNT-5, published in the New England Journal of Medicine, was a direct, randomized, head-to-head trial comparing the two at their maximum tolerated doses in adults with obesity (without diabetes)¹.

The result: at 72 weeks, participants on tirzepatide lost about 20.2% of body weight, versus about 13.7% on semaglutide¹. That is a meaningful difference — roughly a 6.5-percentage-point edge for tirzepatide — and it is the strongest single piece of evidence in this comparison precisely because the two drugs were tested in the same trial, in the same people, at the same time.

But read that result honestly. Both groups lost a great deal of weight; semaglutide's ~13.7% is itself a strong result that would have been considered remarkable a decade ago. Tirzepatide won, but it did not make semaglutide look weak. And SURMOUNT-5 enrolled people without diabetes — weight loss tends to be somewhat smaller in people with type 2 diabetes for both drugs, so these exact numbers do not transfer perfectly to every patient.

Why the indirect numbers line up with this

The head-to-head result is consistent with what the individual trials showed. In STEP 1, once-weekly semaglutide 2.4 mg produced about 14.9% mean weight loss over 68 weeks versus placebo in adults with obesity². In SURMOUNT-1, tirzepatide produced up to about 20.9% weight loss at its highest dose over 72 weeks³. Those separate trials hinted at tirzepatide's edge; SURMOUNT-5 confirmed it directly rather than by cross-trial guesswork.

A network meta-analysis comparing GLP-1 medicines for obesity reached the same broad conclusion — tirzepatide sits at the top of the efficacy ranking for weight loss among the agents studied⁴. The pattern is consistent enough that "tirzepatide tends to produce more weight loss than semaglutide" is a fair, evidence-backed statement.

Side effects: similar categories, real differences in degree

Both drugs share the same dominant side-effect story: gastrointestinal. Nausea, diarrhea, constipation, and vomiting are the most common adverse events for both, they cluster around dose increases, and they tend to ease as the body adjusts. A systematic review and meta-analysis comparing semaglutide and tirzepatide against placebo in people with obesity found that both significantly raise GI adverse events versus placebo, with nausea and diarrhea leading the list for each⁵.

The practical differences are in degree and discontinuation. In SURMOUNT-5, the overall side-effect profiles were broadly similar and consistent with the class, and GI events were the most common reason people struggled — but most were mild to moderate and most people stayed on treatment¹. The takeaway is not "one is gentle and one is harsh." It is that both are GI-heavy drugs, the difference between them is modest, and how slowly you titrate often matters more to your tolerability than which of the two you take. (Our semaglutide dosing and side effects guide covers why slow escalation is the single biggest tolerability lever.)

Both drugs also carry the same class-level safety cautions — a boxed warning about thyroid C-cell tumors based on rodent data, plus warnings about pancreatitis, gallbladder disease, and (for semaglutide) a rare vision signal. Those are class effects, not points of difference. (We cover the semaglutide-specific versions in semaglutide and pancreatitis and semaglutide, gallbladder and kidneys.)

Heart and metabolic outcomes: semaglutide has the longer track record

Here is where the comparison flips. Weight loss is one outcome; cardiovascular protection is another, and on hard outcome data semaglutide currently has the stronger, longer evidence base. The SELECT trial showed semaglutide reduced major adverse cardiovascular events in people with established cardiovascular disease and obesity but without diabetes⁶, and earlier trials (SUSTAIN-6) established cardiovascular benefit in type 2 diabetes⁷. Tirzepatide's dedicated cardiovascular-outcomes trial in this population is still maturing. So if cardiovascular risk reduction — not just the number on the scale — is the goal, semaglutide is the one with proven outcome data today.

A benefit-risk network meta-analysis of newer glucose-lowering drugs reflects this nuance: these agents differ not only in how much weight or glucose they move, but in which outcomes have been formally demonstrated⁸. "Better" depends entirely on which outcome you are optimizing for.

So which is "better"?

Honestly: it depends on the goal.

• •For raw weight loss, the direct head-to-head trial favors tirzepatide (20.2% vs 13.7%)¹.
• •For proven cardiovascular outcome protection, semaglutide has the longer, stronger evidence today⁶⁷.
• •For tolerability, they are broadly similar — both are GI-heavy, and your titration speed and individual response matter more than the brand⁵.
• •For practical access, cost, insurance coverage, and supply often decide it more than efficacy. The drug you can actually get and afford, and tolerate well enough to stay on, beats the theoretically "stronger" one you quit.

Neither is a casual choice — both are prescription drugs with a boxed warning and a real side-effect profile, started and monitored under a clinician. If you are switching from a different drug, our guide on switching from Zepbound to Wegovy walks through how that transition is handled in practice. And whichever you land on, the broader evidence picture is laid out in our semaglutide evidence guide, with provider options compared in our best semaglutide providers roundup.